| 1 |
34353292 | RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. | 2021 Aug 5 |
2 |
| 2 |
31479512 | Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. | 2020 Jun 1 |
1 |
| 3 |
30066234 | Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine. | 2019 Jul |
1 |
| 4 |
30941207 | Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine. | 2019 |
3 |
| 5 |
27737534 | ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. | 2017 Jul |
1 |
| 6 |
28422153 | Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. | 2017 Apr 19 |
1 |
| 7 |
26763622 | Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. | 2016 Aug |
1 |
| 8 |
26137163 | Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. | 2015 Jun |
2 |
| 9 |
26200905 | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. | 2015 |
2 |
| 10 |
26557761 | ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. | 2015 |
1 |
| 11 |
24403499 | Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. | 2014 Jan |
4 |
| 12 |
25227833 | Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. | 2014 |
1 |
| 13 |
23463763 | Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. | 2013 Mar |
1 |
| 14 |
23482788 | Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. | 2013 Mar |
1 |
| 15 |
23982437 | Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. | 2013 Nov |
1 |
| 16 |
24045016 | Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. | 2013 Nov |
3 |
| 17 |
24083589 | Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer. | 2013 Nov |
1 |
| 18 |
24349760 | A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy. | 2013 Sep 1 |
2 |
| 19 |
21676483 | Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. | 2012 Jan |
1 |
| 20 |
22028294 | Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. | 2012 May 1 |
2 |
| 21 |
22302408 | RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. | 2012 May |
2 |
| 22 |
22330686 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. | 2012 Feb 14 |
1 |
| 23 |
22616552 | ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. | 2012 May 22 |
2 |
| 24 |
23086647 | [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer]. | 2012 Sep |
1 |
| 25 |
28920258 | Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. | 2012 Feb |
1 |
| 26 |
19968494 | In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. | 2010 Feb |
1 |
| 27 |
20211060 | [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]. | 2010 Jan |
2 |
| 28 |
20443070 | Impact of biomarkers on non-small cell lung cancer treatment. | 2010 Mar |
2 |
| 29 |
19552012 | [ERCC1 and RRM1 genes in lung cancer]. | 2009 Jul-Aug |
1 |
| 30 |
19667277 | Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. | 2009 Sep 10 |
3 |
| 31 |
19884554 | Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. | 2009 Dec 1 |
3 |
| 32 |
19920864 | Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. | 2009 |
1 |
| 33 |
20082278 | Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. | 2009 Oct-Dec |
1 |
| 34 |
20719134 | [Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.]. | 2009 May 20 |
3 |
| 35 |
18347182 | Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. | 2008 Mar 15 |
2 |
| 36 |
18494946 | mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. | 2008 Jun |
2 |
| 37 |
19578506 | Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. | 2008 Apr 17 |
1 |
| 38 |
21885003 | Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer. | 2008 Mar |
2 |
| 39 |
17534174 | ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. | 2007 Jul |
1 |
| 40 |
17686445 | How could pharmacogenomics help improve patient survival? | 2007 Aug |
1 |
| 41 |
18157593 | [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)]. | 2007 |
2 |
| 42 |
18235415 | [Predicting the response to chemotherapy in patients with non-small cell lung cancer]. | 2007 Oct |
1 |
| 43 |
16690105 | Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. | 2006 Nov |
1 |
| 44 |
16980606 | ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. | 2006 Dec |
3 |
| 45 |
15839954 | Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. | 2005 May-Jun |
1 |
| 46 |
14977831 | Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. | 2004 Feb 15 |
1 |
| 47 |
12504621 | Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. | 2003 Jan |
1 |
| 48 |
12867068 | Genetic testing for chemotherapy in non-small cell lung cancer. | 2003 Aug |
1 |
| 49 |
12917817 | Targeted therapy in combination with gemcitabine in non-small cell lung cancer. | 2003 Aug |
2 |
| 50 |
14668933 | Influence of genetic markers on survival in non-small cell lung cancer. | 2003 Oct |
3 |